Prostate Lesions: What They Are and What Happens Next

A prostate lesion is any abnormal area found in the prostate gland, and the majority turn out to be something other than cancer. The term itself is deliberately vague: it can refer to benign prostatic hyperplasia (BPH), inflammation, a pre-cancerous change, or an actual tumor. When a doctor tells you they’ve found a “lesion,” it typically means something showed up on imaging or a blood test flagged concern, and now a series of steps will determine what that something is. The pathway from discovery to diagnosis has changed dramatically in recent years, with MRI scoring systems, targeted biopsies, and emerging biomarkers all sharpening the process.

What “Prostate Lesion” Actually Means

The prostate sits just below the bladder and surrounds the urethra. It has distinct anatomical zones, and abnormalities can arise in any of them. When imaging picks up something unusual, the radiologist calls it a lesion. That word is clinically neutral: it means “something that looks different from the surrounding tissue.” It says nothing about whether the abnormality is dangerous.

A wide range of benign conditions can look suspicious on imaging. These include BPH nodules, areas of tissue death or scarring, calcifications, hemorrhage from a prior biopsy, and various forms of prostatitis (infection or inflammation of the prostate). Granulomatous prostatitis, for example, can closely mimic cancer on MRI. Even normal anatomical structures like the central zone of the prostate or periprostatic lymph nodes can be mistaken for tumors by less experienced readers. These benign mimics are so common that an entire category of diagnostic research is devoted to telling them apart from actual cancer.¹

This is worth understanding because it reframes the anxiety. A lesion on your report does not mean you have cancer. It means something needs a closer look, and at each stage of that closer look, the odds of it being benign are fairly high.

How Lesions Are Detected in the First Place

Most prostate lesions come to attention through one of two routes: an elevated PSA (prostate-specific antigen) blood test, or an abnormality on imaging done for another reason. PSA is a protein produced by the prostate, and elevated levels can signal cancer, but they also rise with BPH, prostatitis, recent ejaculation, and even vigorous exercise. A single elevated PSA reading is a poor cancer predictor on its own.

To sharpen PSA’s usefulness, doctors increasingly look at PSA density, which divides your PSA level by the volume of your prostate as measured on imaging. A man with a large prostate and a PSA of 8 is in a very different situation from a man with a small prostate and a PSA of 8. Research shows that PSA density outperforms raw PSA change in distinguishing cancer from benign causes, and that combining PSA density with information about how PSA levels have changed over time can further reduce unnecessary biopsies.² One study found that the PSA density threshold giving the best balance of sensitivity and specificity had an area under the curve of 0.83, meaning strong but not perfect diagnostic accuracy.³

If PSA or PSA density raises concern, the next step is usually a multiparametric MRI of the prostate. This is where the lesion gets its formal description.

What Your PI-RADS Score Means

When a radiologist reads your prostate MRI, they assign each suspicious area a PI-RADS score from 1 to 5. PI-RADS stands for the Prostate Imaging Reporting and Data System, and it works like a suspicion meter. A score of 1 means cancer is highly unlikely. A score of 5 means cancer is highly likely. The middle scores represent increasing degrees of uncertainty.

In practical terms, the cancer detection rates climb steeply with each PI-RADS level. One study found that biopsy-confirmed cancer showed up in about 16% of PI-RADS 2 lesions, 26% of PI-RADS 3, 62% of PI-RADS 4, and 89% of PI-RADS 5.⁴ That means even at PI-RADS 4, roughly four in ten biopsied lesions are not cancer. And among those that are cancer, not all are clinically significant, meaning some are slow-growing tumors that may never cause harm.

Here is the uncomfortable truth about PI-RADS, though: how the score is assigned depends partly on who is reading the MRI. A multi-radiologist study found that the cancer detection rate for PI-RADS 3 lesions ranged from 3% to 27% depending on the radiologist, for PI-RADS 4 it ranged from 23% to 65%, and for PI-RADS 5 from 40% to 80%.⁵ The radiologist reading your scan was independently associated with cancer detection alongside the PI-RADS score itself. Agreement among readers is better for larger, more obvious lesions and weaker for smaller or ambiguous ones.⁶ This variability is one reason why getting your MRI read at a center with high prostate-imaging volume can matter.

When and How a Biopsy Happens

If your PI-RADS score is 3 or higher, your doctor will likely recommend a biopsy. The goal is to get tissue samples from the suspicious area so a pathologist can examine the cells under a microscope. There are two broad approaches, and they are often combined.

A systematic biopsy takes samples in a grid pattern across the prostate regardless of where the lesion is. A targeted biopsy uses MRI-ultrasound fusion to guide the needle directly into the suspicious area. The targeted approach is better at finding higher-grade cancers, while the systematic approach catches some cancers the targeted method misses. A landmark trial published in the New England Journal of Medicine found that combining both methods led to cancer diagnoses in about 10% more men than either method alone, and to upgrading the cancer grade in about a fifth of cases. However, if only targeted biopsies had been performed, roughly 9% of clinically significant cancers would have been missed.⁷ For this reason, most guidelines now recommend doing both simultaneously.

MRI-ultrasound fusion biopsies showed higher overall diagnostic accuracy and greater sensitivity compared to systematic biopsies alone, with a particularly stronger ability to detect higher-grade tumors.⁸ This matters because the whole point is catching cancers that need treatment while avoiding unnecessary intervention for those that don’t.

Transrectal Versus Transperineal Approach

Biopsies can be performed through the rectum (transrectal) or through the skin between the scrotum and anus (transperineal). A meta-analysis of prospective studies found no difference in cancer detection rates between the two routes.⁹ Where they differ is infection risk. The transperineal approach reduced the odds of hospitalization for infectious complications by about 77% compared to the transrectal route, and post-procedure fever was also less common.¹⁰ The transperineal route avoids passing a needle through the rectum, which is what drives that infection advantage. Increasingly, centers are shifting toward the transperineal approach, though the transrectal method remains widely used.

What Patients Actually Worry About

Fear of the biopsy procedure is real but tends to be focused in predictable places. When researchers compared anxiety levels in men scheduled for a prostate biopsy versus men scheduled for an MRI, the biopsy group reported substantially higher fear of the procedure itself, fear of pain, and sleep disturbances beforehand. But for both groups, the strongest source of anxiety wasn’t the procedure: it was fear of the results. On a five-point scale, fear of results scored the highest of any category, averaging moderate to high across all patients regardless of which test they were facing.¹¹ Knowing that the physical discomfort of modern biopsies is generally manageable, and that what’s really doing a number on people is the waiting, can at least help you name the feeling.

Pre-Malignant and Indeterminate Results

Not every biopsy comes back as clearly benign or clearly cancer. Two findings land in a grey zone that deserves its own explanation.

High-grade prostatic intraepithelial neoplasia (HGPIN) describes cells that look abnormal under the microscope but haven’t crossed the line into cancer. Think of it as cells misbehaving without having fully committed to becoming malignant. Historically, HGPIN triggered automatic repeat biopsies, but the evidence has shifted. Current data show that in men with isolated HGPIN whose other clinical indicators (PSA trend, MRI findings) are reassuring, the risk of clinically significant cancer is extremely low. Repeat biopsy is no longer recommended solely because of a previous HGPIN finding.¹²

Atypical small acinar proliferation (ASAP) is a different story. ASAP means the pathologist saw a small cluster of glands that look suspicious but there wasn’t enough tissue to confidently call it cancer. In one study using an extended biopsy scheme, repeat biopsy after ASAP found cancer in about 41% of cases, compared to about 19% after HGPIN and about 17% in men re-biopsied for other reasons like persistently elevated PSA.¹³ Because of this high yield, an ASAP finding generally warrants an earlier repeat MRI or biopsy.¹⁴

If Cancer Is Found

When a biopsy confirms prostate cancer, the next question is how aggressive it is. The Gleason grading system, now organized into five grade groups (1 through 5), drives the treatment conversation. Grade group 1 is the least aggressive; grade group 5 is the most. It’s worth knowing that biopsy grading doesn’t always match what’s found if the whole prostate is later removed surgically. One large analysis found that the biopsy grade matched the surgical specimen in about 59% of cases, with the highest agreement at grade groups 2 and 5 and the lowest at grade group 4.¹⁵ That’s not an indictment of the biopsy process; it reflects the reality that a needle samples a tiny fraction of the gland.

Treatment options broadly fall into three categories based on risk level.

Active Surveillance for Low-Risk Cancer

For grade group 1 cancers and some favorable grade group 2 cancers, active surveillance is now the standard approach. This means closely monitoring the cancer with regular PSA tests, MRIs, and occasional repeat biopsies rather than treating immediately. The logic is that many low-grade prostate cancers grow so slowly they will never cause symptoms or shorten life, and treating them exposes men to side effects they didn’t need. Formal protocols differ across centers. Some use more intensive initial testing followed by a looser schedule; others schedule biopsies at regular intervals.¹⁶ If monitoring shows the cancer is progressing, curative treatment can be pursued at that point.

Surgery Versus Radiation for Intermediate and High-Risk Cancer

When treatment is needed, the two main curative options are radical prostatectomy (surgical removal of the prostate) and radiation therapy. A real-world study of 2,600 patients found equally effective cancer control between the two when the analysis adjusted for patient and tumor characteristics, with no differences in metastasis-free survival, cancer-specific survival, or overall survival.¹⁷ An observational study found that among younger and fitter men with intermediate or high-risk cancer, the data trended toward favoring surgery, though the overall differences were modest.¹⁸

The choice between surgery and radiation often comes down to side-effect profiles. Surgery tends to cause more urinary incontinence, while radiation tends to cause more bowel and irritative urinary symptoms. Both affect sexual function, though surgery’s impact is typically more severe. A five-year follow-up study found that men who had radical prostatectomy experienced substantially worse incontinence scores compared to men who had brachytherapy, but fared somewhat better on irritative-obstructive urinary symptoms. Sexual deterioration was steepest after surgery.¹⁹ These treatment-related effects tend to appear early and persist over time.²⁰

Focal Therapy as a Middle Ground

For some men with localized cancer, focal therapy targets just the tumor rather than the entire prostate. Technologies include high-intensity focused ultrasound (HIFU), cryotherapy (freezing), and irreversible electroporation (IRE). A systematic review and meta-analysis found overall survival of 98%, cancer-specific survival above 99%, and low impacts on urinary function in the vast majority of studies. About a fifth of men undergoing follow-up biopsy within two years showed clinically significant cancer, roughly split between the treated area and elsewhere in the gland. The rate of eventually needing radical treatment was about 10.5%.²¹ Focal therapy’s appeal is preserving quality of life while still destroying the cancer, though it requires careful patient selection and close follow-up.

Racial Disparities in Prostate Imaging and Diagnosis

The diagnostic pathway described above doesn’t play out equally for everyone. Black men face higher prostate cancer risk and tend to develop more aggressive disease at younger ages, yet they are less likely to receive a prostate MRI. One study using SEER-Medicare data found that Black patients with prostate cancer were significantly less likely than White patients to receive a prostate MRI (about 6% versus 10%). Roughly 80% of that disparity was explained by geographic differences, neighborhood poverty, residential segregation, and individual socioeconomic factors rather than clinical or tumor characteristics.²² A larger meta-analysis of over 94,000 cases confirmed substantially lower MRI utilization among Black and Hispanic patients.²³

Beyond access, there’s evidence that MRI itself may perform differently across racial groups. One study found that mpMRI’s detection rate for clinically significant cancer in the transition zone of the prostate was lower in African American men (about 67%) than in White men (about 80%), while performance in the peripheral zone was similar. Quantitative MRI measurements also differed between groups in ways not explained by age, PSA level, or prostate size.²⁴ This is still an early area of research, but it raises the possibility that imaging protocols calibrated primarily on one population may be less accurate for others.

Emerging Tools That May Change the Pathway

Two developments are reshaping how prostate lesions get evaluated: blood and urine biomarkers, and artificial intelligence.

Several biomarkers beyond PSA are now available. A review of validation data from 2015 to 2023 found that these newer tests provide enough specificity to allow 15% to 50% of unnecessary biopsies to be skipped while still catching 90% to 95% of clinically significant cancers.²⁵ These biomarkers are particularly useful in the PI-RADS 3 grey zone, where the MRI is equivocal and the decision of whether to biopsy is hardest. Data suggest biomarkers can help inform that decision, potentially sparing men with truly benign lesions from an unnecessary procedure.²⁶

AI-assisted MRI reading is also progressing rapidly. Automated systems trained on large datasets of prostate MRIs can now identify and grade lesions, and researchers are evaluating how their performance compares to experienced radiologists using PI-RADS criteria.²⁷ On the pathology side, a deep learning system for Gleason grading achieved very high agreement with expert pathologists, with area under the curve values above 0.97 for distinguishing between clinically important grade thresholds.²⁸ Given the reader variability in PI-RADS scoring noted earlier, AI tools functioning as a second reader or quality check could help reduce that inconsistency, though they are supplements to radiologist judgment rather than replacements for it.

None of these tools have eliminated the need for tissue diagnosis when suspicion is high. What they are doing is making each step of the pathway more precise, helping distinguish the men who genuinely need a biopsy from those who can safely be monitored, and helping pathologists catch subtle grading differences that affect treatment decisions.